Correction: Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program

Oncogene. 2023 Apr;42(17):1417. doi: 10.1038/s41388-023-02615-8.

D Bello Roufai¹, A Gonçalves², T De La Motte Rouge³, S Akla⁴, C Blonz⁵, J Grenier⁶, J Gligorov^{7

8}, M Saghatchian⁹, C Bailleux¹⁰, H Simon¹¹, I Desmoulins¹², Z Tharin¹², E Renaud¹¹, M Bertho⁵, M-A Benderra⁷, S Delaloge⁴, L Robert³, P Cottu¹³, J Y Pierga^{13

14}, D Loirat¹³, A Bertucci², B Renouf¹³, F C Bidard^{13

15}, F Lerebours¹³

¹ Department of Medical Oncology, Institut Curie, Paris and Saint-Cloud, France. Diana.belloroufai@curie.fr.
² Aix-Marseille Univ, CNRS, INSERM, Department of Medical Oncology, Institut Paoli Calmettes, CRCM, Marseille, France.
³ Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.
⁴ Department of Cancer Medicine, Gustave Roussy, Villejuif, France.
⁵ Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Sait-Herblain and Angers, France.
⁶ Department of Medical Oncology, Institut du Cancer d'Avignon, Avignon, France.
⁷ Department of Medical Oncology, Hôpital Tenon, AP-HP, Paris, France.
⁸ INSERM U938, Institut Universitaire de Cancérologie, AP-HP Sorbonne Université, Paris, France.
⁹ Breast Cancer Unit, American Hospital of Paris, Neuilly-sur-Seine, France.
¹⁰ Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France.
¹¹ Department of Medical Oncology, University Hospital of Brest, Brest, France.
¹² Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.
¹³ Department of Medical Oncology, Institut Curie, Paris and Saint-Cloud, France.
¹⁴ Paris Cité University, Paris, France.
¹⁵ UVSQ, Paris-Saclay University, Saint Cloud, France.

No abstract available

Publication types